Cellectis Цена / Продажи
Что обозначает Цена / Продажи в Cellectis?
Цена / Продажи Cellectis является 6.50
Какое определение для Цена / Продажи?
Соотношение цены и продаж - это цена акций компании по сравнению с её доходами.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Цена / Продажи компаний в Health Care сектор на NASDAQ по сравнению с Cellectis
Что делает Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Компании с цена / продажи похож на Cellectis
- Nyrada имеет Цена / Продажи из 6.49
- PTL Enterprises имеет Цена / Продажи из 6.49
- Dolby Laboratories имеет Цена / Продажи из 6.50
- Hercules Capital Inc имеет Цена / Продажи из 6.50
- Canopy Growth имеет Цена / Продажи из 6.50
- The Crypto имеет Цена / Продажи из 6.50
- Cellectis имеет Цена / Продажи из 6.50
- Hive Blockchain Technologies имеет Цена / Продажи из 6.50
- Marvell Tech. Grp Dl ,002 имеет Цена / Продажи из 6.51
- SWK имеет Цена / Продажи из 6.51
- Schroder European Real Estate Investment Trust Plc имеет Цена / Продажи из 6.51
- NextEra Inc имеет Цена / Продажи из 6.51
- First Trust New Opportunities MLP & Fund имеет Цена / Продажи из 6.51